Skip to main content
Top
Published in: Sports Medicine 6/2008

01-06-2008 | Leading Article

Use of Prescription Drugs in Athletes

Authors: Dr Antti Alaranta, Hannu Alaranta, Ilkka Helenius

Published in: Sports Medicine | Issue 6/2008

Login to get access

Abstract

Although athletes are young and generally healthy, they use a variety of nondoping classified medicines to treat injuries, cure illnesses and obtain a competitive edge. Athletes and sports medicine physicians try to optimize the treatment of symptoms related to extreme training during an elite athlete’s active career. According to several studies, the use of antiasthmatic medication is more frequent among elite athletes than in the general population. The type of training and the kind of sport influence the prevalence of asthma. Asthma is most common among those competing in endurance events, such as cycling, swimming, cross-country skiing and long-distance running. Recent studies show that athletes use also NSAIDs and oral antibacterials more commonly than age-matched controls, especially athletes competing in speed and power sports. Inappropriately high doses and concomitant use of several different NSAIDs has been observed. All medicines have adverse effects that may have deleterious effects on elite athletes’ performance. Thus, any unnecessary medication use should be minimized in elite athletes. Inhaled β2-agonists may cause tachycardia and muscle tremor, which are especially harmful in events requiring accuracy and a steady hand. In experimental animal models of acute injury, especially selective cyclo-oxygenase-2 inhibitors have been shown to be detrimental to tissue-level repair. They have been shown to impair mechanical strength return following acute injury to bone, ligament and tendon. This may have clinical implications for future injury susceptibility. However, it should be noted that the current animal studies have limited translation to the clinical setting. Adverse effects related to the CNS and gastrointestinal adverse reactions are commonly reported in connection with NSAID use also in elite athletes. In addition to the potential for adverse effects, recent studies have shown that NSAID use may negatively regulate muscle growth by inhibiting protein synthesis. Physicians and pharmacists taking care of athletes’ medication need to be aware of the medicines that an athlete is taking and how those medicines interact with performance, exercise, environment and other medicines. Sport associations should repeatedly monitor not only the use of banned substances, but also the trends of use of legal medicines in athletes. Not only physicians and pharmacists, but also athletes and coaches should be better educated with respect to potential benefits and risks, and how each agent may affect an athlete’s performance. The attitudes and beliefs leading to ample use of legal medicines in athletes is an interesting area of future research.
Literature
1.
go back to reference Alaranta A, Alaranta H, Heliövaara M, et al. Allergy and pharmacological management in elite athletes. Med Sci Sports Exerc 2005; 37: 707–11PubMedCrossRef Alaranta A, Alaranta H, Heliövaara M, et al. Allergy and pharmacological management in elite athletes. Med Sci Sports Exerc 2005; 37: 707–11PubMedCrossRef
2.
go back to reference Alaranta A, Alaranta H, Palmu P, et al. Asthma medication in Finnish Olympic athletes: no signs of overuse of inhaled β2—agonists. Med Sci Sports Exerc 2004; 36: 919–24PubMedCrossRef Alaranta A, Alaranta H, Palmu P, et al. Asthma medication in Finnish Olympic athletes: no signs of overuse of inhaled β2—agonists. Med Sci Sports Exerc 2004; 36: 919–24PubMedCrossRef
3.
go back to reference Helenius IJ, Tikkanen HO, Haahtela T. Association between type of training and risk of asthma in elite athletes. Thorax 1997; 52: 157–60PubMedCrossRef Helenius IJ, Tikkanen HO, Haahtela T. Association between type of training and risk of asthma in elite athletes. Thorax 1997; 52: 157–60PubMedCrossRef
4.
go back to reference Helenius IJ, Tikkanen HO, Sarna S, et al. Asthma and increased bronchial responsiveness in elite athletes: atopy and sport event as risk factors. J Allergy Clin Immunol 1998a; 101: 646–52PubMedCrossRef Helenius IJ, Tikkanen HO, Sarna S, et al. Asthma and increased bronchial responsiveness in elite athletes: atopy and sport event as risk factors. J Allergy Clin Immunol 1998a; 101: 646–52PubMedCrossRef
5.
go back to reference Nystad W, Harris J, Sundgot Borgen J. Asthma and wheezing among Norwegian elite athletes. Med Sci Sports Exerc 2000; 32: 266–70PubMedCrossRef Nystad W, Harris J, Sundgot Borgen J. Asthma and wheezing among Norwegian elite athletes. Med Sci Sports Exerc 2000; 32: 266–70PubMedCrossRef
6.
go back to reference Kujala UM, Taimela S, Antti-Poika I, et al. Acute injuries in soccer, ice hockey, volleyball, basketball, judo, and karate: analysis of national registry data. BMJ 1995; 311: 1465–8PubMedCrossRef Kujala UM, Taimela S, Antti-Poika I, et al. Acute injuries in soccer, ice hockey, volleyball, basketball, judo, and karate: analysis of national registry data. BMJ 1995; 311: 1465–8PubMedCrossRef
7.
8.
go back to reference Alaranta A, Alaranta H, Heliövaara M, et al. Ample use of medications in elite athletes. Int J Sports Med 2006; 27: 919–25PubMedCrossRef Alaranta A, Alaranta H, Heliövaara M, et al. Ample use of medications in elite athletes. Int J Sports Med 2006; 27: 919–25PubMedCrossRef
9.
go back to reference Helenius I, Rytilä P, Sarna S, et al. Effect of continuing or finishing high—level sports on airway inflammation, bronchial hyperresponsiveness, and asthma: a 5−year prospective followup study of 42 highly trained swimmers. J Allergy Clin Immunol 2002; 109: 962–8PubMed Helenius I, Rytilä P, Sarna S, et al. Effect of continuing or finishing high—level sports on airway inflammation, bronchial hyperresponsiveness, and asthma: a 5−year prospective followup study of 42 highly trained swimmers. J Allergy Clin Immunol 2002; 109: 962–8PubMed
10.
11.
go back to reference Corrigan B, Kazlauskas R. Medication use in athletes selected for doping control at the Sydney Olympics (2000). Clin J Sports Med 2003; 13: 33–40CrossRef Corrigan B, Kazlauskas R. Medication use in athletes selected for doping control at the Sydney Olympics (2000). Clin J Sports Med 2003; 13: 33–40CrossRef
12.
go back to reference Lewis SC, Langman MJS, Laporte JR, et al. Dose—response relationships between individual nonaspirin nonsteroidal anti inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta—analysis based on individual patient data. Br J Clin Pharmacol 2002; 54: 320–6PubMedCrossRef Lewis SC, Langman MJS, Laporte JR, et al. Dose—response relationships between individual nonaspirin nonsteroidal anti inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta—analysis based on individual patient data. Br J Clin Pharmacol 2002; 54: 320–6PubMedCrossRef
13.
go back to reference Bents RT, Tokish JM, Goldberg L. Ephedrine, pseudoephedrine, and amphetamine prevalence in college hockey players. Phys Sportsmed 2004; 32: 30–4PubMed Bents RT, Tokish JM, Goldberg L. Ephedrine, pseudoephedrine, and amphetamine prevalence in college hockey players. Phys Sportsmed 2004; 32: 30–4PubMed
14.
go back to reference Alaranta A, Alaranta H, Holmila J, et al. Self—reported attitudes of elite athletes towards doping: differences between type of sport. Int J Sports Med 2006; 27: 842–6PubMedCrossRef Alaranta A, Alaranta H, Holmila J, et al. Self—reported attitudes of elite athletes towards doping: differences between type of sport. Int J Sports Med 2006; 27: 842–6PubMedCrossRef
15.
go back to reference Huang S-H, Johnson K, Pipe AL. The use of dietary supplements and medications by Canadian athletes at the Atlanta and Sydney Olympic games. Clin J Sport Med 2006; 16: 27–33PubMedCrossRef Huang S-H, Johnson K, Pipe AL. The use of dietary supplements and medications by Canadian athletes at the Atlanta and Sydney Olympic games. Clin J Sport Med 2006; 16: 27–33PubMedCrossRef
16.
go back to reference Weiler JM. Medical modifiers of sport injury: the use of non—steroidal anti—inflammatory drugs (NSAIDs) in sports soft tissue injury. Clin Sports Med 1992; 11: 625–44PubMed Weiler JM. Medical modifiers of sport injury: the use of non—steroidal anti—inflammatory drugs (NSAIDs) in sports soft tissue injury. Clin Sports Med 1992; 11: 625–44PubMed
17.
go back to reference Shoor S. Athletes, nonsteroidal anti—inflammatory drugs, coxibs, and the gastrointestinal tract. Curr Sports Med Reports 2002; 1: 107–15 Shoor S. Athletes, nonsteroidal anti—inflammatory drugs, coxibs, and the gastrointestinal tract. Curr Sports Med Reports 2002; 1: 107–15
18.
go back to reference Thorsson O, Rantanen J, Hurme T, et al. Effects of nonsteroidal antiinflammatory medication on satellite cell proliferation during muscle regeneration. Am J Sports Med 1998; 26: 172–6PubMed Thorsson O, Rantanen J, Hurme T, et al. Effects of nonsteroidal antiinflammatory medication on satellite cell proliferation during muscle regeneration. Am J Sports Med 1998; 26: 172–6PubMed
19.
go back to reference Almekinders LC. Anti—inflammatory treatment of muscular injuries in sport: an update of recent studies. Sports Med 1999; 28: 383–8PubMedCrossRef Almekinders LC. Anti—inflammatory treatment of muscular injuries in sport: an update of recent studies. Sports Med 1999; 28: 383–8PubMedCrossRef
20.
go back to reference Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin—like drugs. Nat New Biol 1971; 231: 232–5PubMed Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin—like drugs. Nat New Biol 1971; 231: 232–5PubMed
21.
22.
go back to reference Gilroy DW, Colville-Nash PR, Willis D, et al. Inducible cyclooxygenase may have anti—inflammatory properties. Nat Med 1999; 5: 698–701PubMedCrossRef Gilroy DW, Colville-Nash PR, Willis D, et al. Inducible cyclooxygenase may have anti—inflammatory properties. Nat Med 1999; 5: 698–701PubMedCrossRef
23.
go back to reference Singh P, Roberts MS. Skin permeability and local tissue concentration of nonsteroidal anti—inflammatory drugs after topical application. J Pharmacol Exp Ther 1994; 268: 144–51PubMed Singh P, Roberts MS. Skin permeability and local tissue concentration of nonsteroidal anti—inflammatory drugs after topical application. J Pharmacol Exp Ther 1994; 268: 144–51PubMed
24.
go back to reference Moore RA, Tramer MR, Carroll D, et al. Quantitative systemic review of topically applied non—steroidal anti—inflammtory drugs. BMJ 1998; 316: 333–8PubMedCrossRef Moore RA, Tramer MR, Carroll D, et al. Quantitative systemic review of topically applied non—steroidal anti—inflammtory drugs. BMJ 1998; 316: 333–8PubMedCrossRef
25.
go back to reference Åkermark C, Forsskåhl B. Topical Indomethacin in overuse injuries in athletes: a randomized double blind comparing elmetacin with oral indomethacin and placebo. Int J Sports Med 1990; 11: 393–6PubMedCrossRef Åkermark C, Forsskåhl B. Topical Indomethacin in overuse injuries in athletes: a randomized double blind comparing elmetacin with oral indomethacin and placebo. Int J Sports Med 1990; 11: 393–6PubMedCrossRef
26.
go back to reference Galer BS, Rowbotham M, Perander J. Topical diclofenac patch relieves minor sport injury pain: results of a multicenter controlled clinical trial. J Pain Symptom Manage 2000; 19: 287–94PubMedCrossRef Galer BS, Rowbotham M, Perander J. Topical diclofenac patch relieves minor sport injury pain: results of a multicenter controlled clinical trial. J Pain Symptom Manage 2000; 19: 287–94PubMedCrossRef
27.
go back to reference Mazieres B, Rouanet S, Velicy J, et al. Topical ketoprofen patch (100mg) for the treatment of ankle sprain. Am J Sports Med 2005; 33: 515–22PubMedCrossRef Mazieres B, Rouanet S, Velicy J, et al. Topical ketoprofen patch (100mg) for the treatment of ankle sprain. Am J Sports Med 2005; 33: 515–22PubMedCrossRef
28.
go back to reference Predel HG, Koll R, Pabst H, et al. Diclofenac patch for topical treatment of acute impact injuries: a randomized, double blind, placebo controlled, multicentre study. Br J Sports Med 2004; 38: 318–23PubMedCrossRef Predel HG, Koll R, Pabst H, et al. Diclofenac patch for topical treatment of acute impact injuries: a randomized, double blind, placebo controlled, multicentre study. Br J Sports Med 2004; 38: 318–23PubMedCrossRef
29.
go back to reference Esparza F, Cobian C, Jimenez JF, et al. Topical ketoprofen TDS patch versus diclofenac gel: efficacy and tolerability in benign sport related soft—tissue injuries. Br J Sports Med 2007; 41: 134–9PubMedCrossRef Esparza F, Cobian C, Jimenez JF, et al. Topical ketoprofen TDS patch versus diclofenac gel: efficacy and tolerability in benign sport related soft—tissue injuries. Br J Sports Med 2007; 41: 134–9PubMedCrossRef
30.
go back to reference Almekinders LC, Gilbert JA. Healing of experimental muscles strains and the effects of nonsteroidal anti-inflammatory medication. Am J Sports Med 1986; 14: 303–8PubMedCrossRef Almekinders LC, Gilbert JA. Healing of experimental muscles strains and the effects of nonsteroidal anti-inflammatory medication. Am J Sports Med 1986; 14: 303–8PubMedCrossRef
31.
go back to reference Reynolds JF, Noakes T, Schwellnus MP. Nonsteroidal anti inflammatory drugs fail to enhance healing of acute hamstring injuries treated with physiotherapy. S Afr Med J 1995; 85: 517–22PubMed Reynolds JF, Noakes T, Schwellnus MP. Nonsteroidal anti inflammatory drugs fail to enhance healing of acute hamstring injuries treated with physiotherapy. S Afr Med J 1995; 85: 517–22PubMed
32.
go back to reference Bondesen BA, Mills ST, Kegley KM, et al. The COX−2 pathway is essential during early stages of skeletal muscle regeneration. Am J Physiol Cell Physiol 2004; 287: C475–83CrossRef Bondesen BA, Mills ST, Kegley KM, et al. The COX−2 pathway is essential during early stages of skeletal muscle regeneration. Am J Physiol Cell Physiol 2004; 287: C475–83CrossRef
33.
go back to reference Rahusen FT, Weinhold PS, Almekinders LC. Nonsteroidal anti—inflammatory drugs and acetaminophen in the treatment of an acute muscle injury. Am J Sports Med 2004; 32: 1856–9PubMedCrossRef Rahusen FT, Weinhold PS, Almekinders LC. Nonsteroidal anti—inflammatory drugs and acetaminophen in the treatment of an acute muscle injury. Am J Sports Med 2004; 32: 1856–9PubMedCrossRef
34.
go back to reference Dalton JD, Schweinie JE. Randomized controlled noninferiority trial to compare extended release acetaminophen and ibuprofen for the treatment of ankle sprains. Ann Emerg Med 2006; 48: 615–23PubMedCrossRef Dalton JD, Schweinie JE. Randomized controlled noninferiority trial to compare extended release acetaminophen and ibuprofen for the treatment of ankle sprains. Ann Emerg Med 2006; 48: 615–23PubMedCrossRef
35.
go back to reference Woo WWK, Man SY, Lam PKW, et al. Randomized doubleblind trial comparing oral paracetamol and oral nonsteroidal antiinflammatory drugs for treating pain after musculoskeletal injury. Ann Emerg Med 2005; 46: 352–61PubMedCrossRef Woo WWK, Man SY, Lam PKW, et al. Randomized doubleblind trial comparing oral paracetamol and oral nonsteroidal antiinflammatory drugs for treating pain after musculoskeletal injury. Ann Emerg Med 2005; 46: 352–61PubMedCrossRef
36.
go back to reference Almekinders LC. Nonsteroidal anti—inflammatory drugs and corticosteroids. In: Bahrke MS, Yesalis CE, editors. Performance—enhancing substances in sport and exercise. Champaign (IL): Human Kinetics, 2002: 125–35 Almekinders LC. Nonsteroidal anti—inflammatory drugs and corticosteroids. In: Bahrke MS, Yesalis CE, editors. Performance—enhancing substances in sport and exercise. Champaign (IL): Human Kinetics, 2002: 125–35
37.
go back to reference Peterson JM, Trappe TA, Mylona E, et al. Ibuprofen and acetaminophen: effect on muscle inflammation after eccentric exercise. Med Sci Sports Exerc 2003; 35: 892–6PubMedCrossRef Peterson JM, Trappe TA, Mylona E, et al. Ibuprofen and acetaminophen: effect on muscle inflammation after eccentric exercise. Med Sci Sports Exerc 2003; 35: 892–6PubMedCrossRef
38.
go back to reference Bourgeois J, Macdougal D, Macdonald J, et al. Naproxen does not alter indices of muscle damage in resistance—exercised trained men. Med Sci Sports Exerc 1999; 31: 4–9PubMedCrossRef Bourgeois J, Macdougal D, Macdonald J, et al. Naproxen does not alter indices of muscle damage in resistance—exercised trained men. Med Sci Sports Exerc 1999; 31: 4–9PubMedCrossRef
39.
go back to reference Pizza FX, Cavender D, Stockard A, et al. Anti—inflammatory doses of ibuprofen: effects on neutrophils and exercise—induced muscle injury. Int J Sports Med 1999; 20: 98–102PubMed Pizza FX, Cavender D, Stockard A, et al. Anti—inflammatory doses of ibuprofen: effects on neutrophils and exercise—induced muscle injury. Int J Sports Med 1999; 20: 98–102PubMed
40.
go back to reference Nosaka K, Sakamoto K, Newton M, et al. How long does the protective effect on eccentric exercise—induced muscle damage last? Med Sci Sports Exerc 2001; 33: 1490–5PubMedCrossRef Nosaka K, Sakamoto K, Newton M, et al. How long does the protective effect on eccentric exercise—induced muscle damage last? Med Sci Sports Exerc 2001; 33: 1490–5PubMedCrossRef
41.
go back to reference Barnett A. Using recovery modalities between training sessions in elite athletes: does it help? Sport Med 2006; 36: 781–96CrossRef Barnett A. Using recovery modalities between training sessions in elite athletes: does it help? Sport Med 2006; 36: 781–96CrossRef
42.
go back to reference Lanier AB. Use of nonsteroidal anti—inflammatory drugs following exercise—induced muscle injury. Sports Med 2003; 33: 177–86CrossRef Lanier AB. Use of nonsteroidal anti—inflammatory drugs following exercise—induced muscle injury. Sports Med 2003; 33: 177–86CrossRef
43.
go back to reference Banovac K, Williams JM, Patrick LD, et al. Prevention of heterotopic ossification after spinal cord injury with COX−2 selective inhibitor (rofecoxib). Spinal Cord 2004; 42: 707–10PubMedCrossRef Banovac K, Williams JM, Patrick LD, et al. Prevention of heterotopic ossification after spinal cord injury with COX−2 selective inhibitor (rofecoxib). Spinal Cord 2004; 42: 707–10PubMedCrossRef
44.
go back to reference Mehallo CJ, Dezner JA, Bytomski JR. Practical management: nonsteroidal anti—inflammatory drug (NSAID) use in athletic injuries. Clin J Sport Med 2006; 16: 170–4PubMedCrossRef Mehallo CJ, Dezner JA, Bytomski JR. Practical management: nonsteroidal anti—inflammatory drug (NSAID) use in athletic injuries. Clin J Sport Med 2006; 16: 170–4PubMedCrossRef
45.
go back to reference Altman RD, Latta LL, Keer R, et al. Effect of nonsteroidal anti inflammatory drugs on fracture healing: a laboratory study in rats. J Orthop Trauma 1995; 9: 392–400PubMedCrossRef Altman RD, Latta LL, Keer R, et al. Effect of nonsteroidal anti inflammatory drugs on fracture healing: a laboratory study in rats. J Orthop Trauma 1995; 9: 392–400PubMedCrossRef
46.
go back to reference Burd TA, Lowry KJ, Anglen JO. Indomethacin compared with localized irradiation for the prevention of heterotopic ossification following surgical treatment of acetabular fractures. J Bone Joint Surg Am 2001; 83: 1783–8PubMed Burd TA, Lowry KJ, Anglen JO. Indomethacin compared with localized irradiation for the prevention of heterotopic ossification following surgical treatment of acetabular fractures. J Bone Joint Surg Am 2001; 83: 1783–8PubMed
47.
go back to reference Endo K, Sairyo K, Komatsubara S, et al. Cyclooxygenase−2 inhibitor inhibits the fracture healing. J Physiol Anthropol Appl Human Sci 2002; 21: 235–8PubMedCrossRef Endo K, Sairyo K, Komatsubara S, et al. Cyclooxygenase−2 inhibitor inhibits the fracture healing. J Physiol Anthropol Appl Human Sci 2002; 21: 235–8PubMedCrossRef
48.
go back to reference Bergenstock M, Min W, Simon AM, et al. A comparison between the effects of acetaminophen and celecoxib on bone fracture healing in rats. J Orthop Trauma 2005; 19: 717–23PubMedCrossRef Bergenstock M, Min W, Simon AM, et al. A comparison between the effects of acetaminophen and celecoxib on bone fracture healing in rats. J Orthop Trauma 2005; 19: 717–23PubMedCrossRef
49.
go back to reference Simon AM, Manigrasso MB, O’Connor JP. Cyclo—oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002; 17: 963–76PubMedCrossRef Simon AM, Manigrasso MB, O’Connor JP. Cyclo—oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002; 17: 963–76PubMedCrossRef
50.
go back to reference Zhang X, Schwarz EM, Young DA, et al. Cyclooxygenase−2 regulates mesenchymial cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002; 109: 1405–15PubMed Zhang X, Schwarz EM, Young DA, et al. Cyclooxygenase−2 regulates mesenchymial cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002; 109: 1405–15PubMed
51.
go back to reference Elder CL, Dahners LE, Weinhold PS. A cyclooxygenase−2 inhibitor impairs ligament healing in the rat. Am J Sports Med 2001; 29: 801–5PubMed Elder CL, Dahners LE, Weinhold PS. A cyclooxygenase−2 inhibitor impairs ligament healing in the rat. Am J Sports Med 2001; 29: 801–5PubMed
52.
go back to reference Khan KM, Bonar F, Harcourt P, et al. Histopathology of common tendinopathies: update and implications for clinical management. Sports Med 1999; 27: 393–408PubMedCrossRef Khan KM, Bonar F, Harcourt P, et al. Histopathology of common tendinopathies: update and implications for clinical management. Sports Med 1999; 27: 393–408PubMedCrossRef
53.
go back to reference Paavola M, Kannus P, Orava S, et al. Surgical treatment for chronic Achilles tendinopathy: a prospective seven month follow up study. Br J Sports Med 2002; 36: 178–82PubMedCrossRef Paavola M, Kannus P, Orava S, et al. Surgical treatment for chronic Achilles tendinopathy: a prospective seven month follow up study. Br J Sports Med 2002; 36: 178–82PubMedCrossRef
54.
go back to reference Rodemann HP, Goldberg AL. Arachidonic acid, prostaglandin E2 and F2α influence rates of protein turnover in skeletal and cardiac muscle. J Biol Chem 1982; 257: 1632–8PubMed Rodemann HP, Goldberg AL. Arachidonic acid, prostaglandin E2 and F influence rates of protein turnover in skeletal and cardiac muscle. J Biol Chem 1982; 257: 1632–8PubMed
55.
go back to reference Trappe TA, Fluckey JD, White F, et al. Skeletal muscle PGF2α and PGE2 in response to eccentric exercise: influence of ibuprofen and acetaminophen. J Clin Endocrinol Metab 2001; 86: 5067–70PubMedCrossRef Trappe TA, Fluckey JD, White F, et al. Skeletal muscle PGF2α and PGE2 in response to eccentric exercise: influence of ibuprofen and acetaminophen. J Clin Endocrinol Metab 2001; 86: 5067–70PubMedCrossRef
56.
go back to reference Trappe TA, White F, Lambert CP, et al. Effect of ibuprofen and acetaminophen on postexercise muscle protein synthesis. Am J Physiol Endocrinol Metab 2002; 282: E551–6 Trappe TA, White F, Lambert CP, et al. Effect of ibuprofen and acetaminophen on postexercise muscle protein synthesis. Am J Physiol Endocrinol Metab 2002; 282: E551–6
57.
go back to reference Soltow QA, Betters JL, Sellman JE, et al. Ibuprofen inhibits skeletal muscle hypertrophy in rats. Med Sci Sports Exerc 2006; 38: 840–6PubMedCrossRef Soltow QA, Betters JL, Sellman JE, et al. Ibuprofen inhibits skeletal muscle hypertrophy in rats. Med Sci Sports Exerc 2006; 38: 840–6PubMedCrossRef
58.
go back to reference Hawke TJ, Garry DJ. Myogenic satellite cells: physiology to molecular biology. J Appl Physiol 2001; 91: 534–51PubMed Hawke TJ, Garry DJ. Myogenic satellite cells: physiology to molecular biology. J Appl Physiol 2001; 91: 534–51PubMed
59.
go back to reference Schultz E, Mc Cormick KM. Skeletal muscle satellite cells. Rev Physiol Biochem Pharmacol 1994; 123: 213–57PubMedCrossRef Schultz E, Mc Cormick KM. Skeletal muscle satellite cells. Rev Physiol Biochem Pharmacol 1994; 123: 213–57PubMedCrossRef
60.
go back to reference Mackey AL, Kjaer M, Dandanell S, et al. The influence of anti inflammatory medication on exercise—induced myogenic precursor cell responses in humans. J Appl Physiol 2007; 103: 425–31PubMedCrossRef Mackey AL, Kjaer M, Dandanell S, et al. The influence of anti inflammatory medication on exercise—induced myogenic precursor cell responses in humans. J Appl Physiol 2007; 103: 425–31PubMedCrossRef
61.
go back to reference Hawkey CJ, Langman MS. Non—steroidal anti—inflammatory drugs: overall risks and management. Complementary roles for COX−2 inhibitors and proton pump inhibitors. Gut 2003; 52: 600–8PubMedCrossRef Hawkey CJ, Langman MS. Non—steroidal anti—inflammatory drugs: overall risks and management. Complementary roles for COX−2 inhibitors and proton pump inhibitors. Gut 2003; 52: 600–8PubMedCrossRef
62.
go back to reference Verrico MM, Weber RJ, Mc Kaveney TP, et al. Adverse drug events involving COX−2 inhibitors. Ann Pharmacother 2003; 37: 1203–13PubMedCrossRef Verrico MM, Weber RJ, Mc Kaveney TP, et al. Adverse drug events involving COX−2 inhibitors. Ann Pharmacother 2003; 37: 1203–13PubMedCrossRef
63.
go back to reference Baker J, Cotter JD, Gerrard DF, et al. Effects of indomethacin and celecoxib on renal function in athletes. Med Sci Sports Exerc 2005; 37: 712–7PubMedCrossRef Baker J, Cotter JD, Gerrard DF, et al. Effects of indomethacin and celecoxib on renal function in athletes. Med Sci Sports Exerc 2005; 37: 712–7PubMedCrossRef
64.
go back to reference Walker RJ, Fawcett JP, Flannery EM, et al. Indomethacin potentiates exercise—induced reduction in renal hemodynamics in athletes. Med Sci Sports Exerc 1994; 26: 1302–6PubMed Walker RJ, Fawcett JP, Flannery EM, et al. Indomethacin potentiates exercise—induced reduction in renal hemodynamics in athletes. Med Sci Sports Exerc 1994; 26: 1302–6PubMed
65.
go back to reference Griffiths ML. End—stage renal failure caused by regular use of anti—inflammatory analgesic medication for minor sports injuries. S Afr Med J 1992; 81: 377–8PubMed Griffiths ML. End—stage renal failure caused by regular use of anti—inflammatory analgesic medication for minor sports injuries. S Afr Med J 1992; 81: 377–8PubMed
66.
go back to reference Rashad S, Hemingway A, Rainsford KD, et al. Effect of non steroidal anti—inflammatory drugs on the course of osteoarthritis. Lancet 1989; II: 519–21CrossRef Rashad S, Hemingway A, Rainsford KD, et al. Effect of non steroidal anti—inflammatory drugs on the course of osteoarthritis. Lancet 1989; II: 519–21CrossRef
67.
go back to reference Reijman M, Bierma-Zeinstra SMA, Pols HAP, et al. Is there an association between the use of different types of nonsteroidal anti—inflammatory drugs and radiologic progression of osteoarthritis? Arthritis Rheum 2005; 52: 3137–42PubMedCrossRef Reijman M, Bierma-Zeinstra SMA, Pols HAP, et al. Is there an association between the use of different types of nonsteroidal anti—inflammatory drugs and radiologic progression of osteoarthritis? Arthritis Rheum 2005; 52: 3137–42PubMedCrossRef
68.
go back to reference Seibert K, Zhang Y, Leahy K, et al. Distribution of COX−1 and COX−2 in normal and inflamed tissues. Adv Exp Med Biol 1997; 400A: 167–70PubMedCrossRef Seibert K, Zhang Y, Leahy K, et al. Distribution of COX−1 and COX−2 in normal and inflamed tissues. Adv Exp Med Biol 1997; 400A: 167–70PubMedCrossRef
69.
go back to reference Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX−2 inhibitors. JAMA 2001; 286: 954–9PubMedCrossRef Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX−2 inhibitors. JAMA 2001; 286: 954–9PubMedCrossRef
70.
go back to reference Ray WA, Stein M, Daugherty JR, et al. COX−2 selective non steroidal anti—inflammatory drugs and risk if serious coronary heart disease. Lancet 2002; 360: 1071–3PubMedCrossRef Ray WA, Stein M, Daugherty JR, et al. COX−2 selective non steroidal anti—inflammatory drugs and risk if serious coronary heart disease. Lancet 2002; 360: 1071–3PubMedCrossRef
71.
go back to reference Gilroy DW, Tomlinson A, Willoughby DA. Differential effects of inhibition of isoforms of cyclooxygenase (COX−1, COX−2) in chronic inflammation. Inflamm Res 1998; 47: 79–85PubMedCrossRef Gilroy DW, Tomlinson A, Willoughby DA. Differential effects of inhibition of isoforms of cyclooxygenase (COX−1, COX−2) in chronic inflammation. Inflamm Res 1998; 47: 79–85PubMedCrossRef
72.
go back to reference Gretzer B, Knorth H, Chantrain M, et al. Effects of diclofenac and L−745,337, a selective cyclooxygenase−2 inhibitor, on prostaglandin E2 formation in tissue from human colonic mucosa and chronic bursitis. Gastroenterology 1998; 114: A139CrossRef Gretzer B, Knorth H, Chantrain M, et al. Effects of diclofenac and L−745,337, a selective cyclooxygenase−2 inhibitor, on prostaglandin E2 formation in tissue from human colonic mucosa and chronic bursitis. Gastroenterology 1998; 114: A139CrossRef
73.
go back to reference Wallace JL, Chapman K, Mc Knight W. Limited anti—inflammatory efficacy of cyclo—oxygenase−2 inhibition in carrageenanairpouch inflammation. Br J Pharmacol 1999; 126: 1200–4PubMedCrossRef Wallace JL, Chapman K, Mc Knight W. Limited anti—inflammatory efficacy of cyclo—oxygenase−2 inhibition in carrageenanairpouch inflammation. Br J Pharmacol 1999; 126: 1200–4PubMedCrossRef
74.
go back to reference Gierer P, Mittlmeier T, Bordel R, et al. Selective cyclooxygenase−2 inhibition reverses microcirculatory and inflammatory sequelae of closed soft—tissue trauma in an animal model. J Bone Joint Surg Am 2005; 87: 153–60PubMedCrossRef Gierer P, Mittlmeier T, Bordel R, et al. Selective cyclooxygenase−2 inhibition reverses microcirculatory and inflammatory sequelae of closed soft—tissue trauma in an animal model. J Bone Joint Surg Am 2005; 87: 153–60PubMedCrossRef
75.
go back to reference Anderson SD, Fitch K, Perry CP, et al. Responses to bronchial challenge submitted for approval to use inhaled β2—agonists before an event at the 2002 winter Olympics. J Allergy Clin Immunol 2003; 111: 45–50PubMedCrossRef Anderson SD, Fitch K, Perry CP, et al. Responses to bronchial challenge submitted for approval to use inhaled β2—agonists before an event at the 2002 winter Olympics. J Allergy Clin Immunol 2003; 111: 45–50PubMedCrossRef
77.
go back to reference Kerrebijn KF, van Essen-Zandvliet EEM, Neijens HJ. Effects of long—term treatment with inhaled corticosteroids and betaagonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol 1987; 79: 653–9PubMedCrossRef Kerrebijn KF, van Essen-Zandvliet EEM, Neijens HJ. Effects of long—term treatment with inhaled corticosteroids and betaagonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol 1987; 79: 653–9PubMedCrossRef
78.
go back to reference Vathenen AS, Knox AJ, Higgins BG, et al. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988; I: 554–8CrossRef Vathenen AS, Knox AJ, Higgins BG, et al. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988; I: 554–8CrossRef
79.
go back to reference Cockcroft DW, Mc Parland CP, Britto SA, et al. Regular inhaled albuterol and airway responsiveness to allergen. Lancet 1993; 342: 833–7PubMedCrossRef Cockcroft DW, Mc Parland CP, Britto SA, et al. Regular inhaled albuterol and airway responsiveness to allergen. Lancet 1993; 342: 833–7PubMedCrossRef
80.
go back to reference Cockcroft DW, O’Byrne PM, Swystun VA, et al. Regular use of inhaled albuterol and the allergen—induced late asthmatic response. J Allergy Clin Immunol 1995; 96: 44–9PubMedCrossRef Cockcroft DW, O’Byrne PM, Swystun VA, et al. Regular use of inhaled albuterol and the allergen—induced late asthmatic response. J Allergy Clin Immunol 1995; 96: 44–9PubMedCrossRef
81.
go back to reference Gauvreau GM, Jordana M, Watson RM, et al. Effect of regular inhaled albuterol on allergen—induced late responses and sputum eosinophils in asthmatic subjects. Am J Respir Care Med 1997; 156: 1738–45 Gauvreau GM, Jordana M, Watson RM, et al. Effect of regular inhaled albuterol on allergen—induced late responses and sputum eosinophils in asthmatic subjects. Am J Respir Care Med 1997; 156: 1738–45
82.
go back to reference Nelson JA, Strauss L, Skowronski M, et al. Effect of long—term salmeterol treatment on exercise—induced asthma. N Engl J Med 1998; 339: 141–6PubMedCrossRef Nelson JA, Strauss L, Skowronski M, et al. Effect of long—term salmeterol treatment on exercise—induced asthma. N Engl J Med 1998; 339: 141–6PubMedCrossRef
83.
go back to reference Pauwels RA, Löfdahl CG, Postma D, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405–11PubMedCrossRef Pauwels RA, Löfdahl CG, Postma D, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405–11PubMedCrossRef
84.
go back to reference Ferrari M, Balestreri F, Baratieri S, et al. Evidence of the rapid protective effect of formoterol dry—powder inhalation against exercise—induced bronchospasm in athletes with asthma. Respiration 2000; 67: 510–3PubMedCrossRef Ferrari M, Balestreri F, Baratieri S, et al. Evidence of the rapid protective effect of formoterol dry—powder inhalation against exercise—induced bronchospasm in athletes with asthma. Respiration 2000; 67: 510–3PubMedCrossRef
85.
go back to reference Kindermann W. Do inhaled β2—agonists have an ergogenic potential in non—asthmatic competitive athletes? Sports Med 2007; 37 (2): 95–102PubMedCrossRef Kindermann W. Do inhaled β2—agonists have an ergogenic potential in non—asthmatic competitive athletes? Sports Med 2007; 37 (2): 95–102PubMedCrossRef
86.
go back to reference Martineau L, Horan MA, Rothwell NJ, et al. Salbutamol a beta 2−adrenoceptor antagonist, increases, skeletal muscle strength in young men. Clin Sci 1992; 83: 616–21 Martineau L, Horan MA, Rothwell NJ, et al. Salbutamol a beta 2−adrenoceptor antagonist, increases, skeletal muscle strength in young men. Clin Sci 1992; 83: 616–21
87.
go back to reference Collomp K, Candau R, Lasne F, et al. Effects of short—term oral salbutamol administration on exercise endurance and metabolism. J Appl Physiol 2000; 89: 430–6PubMed Collomp K, Candau R, Lasne F, et al. Effects of short—term oral salbutamol administration on exercise endurance and metabolism. J Appl Physiol 2000; 89: 430–6PubMed
88.
go back to reference Haahtela T, Klaukka T, Koskela K, et al. Asthma programme in Finland: a community problem needs community solutions. Thorax 2001; 56: 806–14PubMedCrossRef Haahtela T, Klaukka T, Koskela K, et al. Asthma programme in Finland: a community problem needs community solutions. Thorax 2001; 56: 806–14PubMedCrossRef
89.
go back to reference Helenius IJ, Rytilä P, Metso T, et al. Respiratory symptoms, bronchial responsiveness and cellular characteristics of induced sputum in elite swimmers. Allergy 1998c; 53: 346–52PubMedCrossRef Helenius IJ, Rytilä P, Metso T, et al. Respiratory symptoms, bronchial responsiveness and cellular characteristics of induced sputum in elite swimmers. Allergy 1998c; 53: 346–52PubMedCrossRef
90.
go back to reference Lumme A, Haahtela T, Öunap J, et al. Airway inflammation, bronchial hyperresponsiveness, and asthma in elite ice hockey players. Eur Respir J 2003; 22: 113–7PubMedCrossRef Lumme A, Haahtela T, Öunap J, et al. Airway inflammation, bronchial hyperresponsiveness, and asthma in elite ice hockey players. Eur Respir J 2003; 22: 113–7PubMedCrossRef
91.
93.
go back to reference Haahtela T, Järvinen M, Kava T, et al. Comparison of a beta 2−agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388–92PubMedCrossRef Haahtela T, Järvinen M, Kava T, et al. Comparison of a beta 2−agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388–92PubMedCrossRef
94.
go back to reference Haahtela T, Järvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331: 700–5PubMedCrossRef Haahtela T, Järvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331: 700–5PubMedCrossRef
95.
go back to reference Barnes PJ. Effect of corticosteroids on airway hyperresponsiveness. Am Rev Respir Dis 1990; 141: S70–6 Barnes PJ. Effect of corticosteroids on airway hyperresponsiveness. Am Rev Respir Dis 1990; 141: S70–6
96.
go back to reference Smith BW, Labotz M. Pharmacologic treatment of exercise induced asthma. Clin J Sports Med 1998; 17: 343–63CrossRef Smith BW, Labotz M. Pharmacologic treatment of exercise induced asthma. Clin J Sports Med 1998; 17: 343–63CrossRef
97.
go back to reference Bel EH, Timmers MC, Zwinderman AH, et al. The effect of inhaled corticosteroids on the maximal degree of airway narrowing to methacholine in asthmatic subjects. Am Rev Respir Dis 1991; 143: 109–13PubMed Bel EH, Timmers MC, Zwinderman AH, et al. The effect of inhaled corticosteroids on the maximal degree of airway narrowing to methacholine in asthmatic subjects. Am Rev Respir Dis 1991; 143: 109–13PubMed
98.
go back to reference Helenius I, Haahtela T. Allergy and asthma in elite summer sport athletes. J Allergy Clin Immunol 2000; 106: 444–52PubMedCrossRef Helenius I, Haahtela T. Allergy and asthma in elite summer sport athletes. J Allergy Clin Immunol 2000; 106: 444–52PubMedCrossRef
99.
go back to reference Helenius I, Lumme A, Haahtela T. Asthma, airway inflammation and treatment in elite athletes. Sports Med 2005; 35: 565–74PubMedCrossRef Helenius I, Lumme A, Haahtela T. Asthma, airway inflammation and treatment in elite athletes. Sports Med 2005; 35: 565–74PubMedCrossRef
100.
go back to reference Bonini S, Brusasco V, Carlsen KH, et al. Diagnosis of asthma and permitted use of inhaled beta2−agonists in athletes. Allergy 2004; 59: 33–6PubMedCrossRef Bonini S, Brusasco V, Carlsen KH, et al. Diagnosis of asthma and permitted use of inhaled beta2−agonists in athletes. Allergy 2004; 59: 33–6PubMedCrossRef
101.
go back to reference Drazen JM, Israel E, O’Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340: 197–206PubMedCrossRef Drazen JM, Israel E, O’Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340: 197–206PubMedCrossRef
102.
go back to reference Reiss TF, Hill JB, Harman E, et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise—induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997; 52: 1030–5PubMedCrossRef Reiss TF, Hill JB, Harman E, et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise—induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997; 52: 1030–5PubMedCrossRef
103.
go back to reference Knapp HR. Reduced allergen—induced nasal congestion and leukotriene synthesis with orally active 5−lipoxygenase inhibitor. N Engl J Med 1990; 323: 1745–8PubMedCrossRef Knapp HR. Reduced allergen—induced nasal congestion and leukotriene synthesis with orally active 5−lipoxygenase inhibitor. N Engl J Med 1990; 323: 1745–8PubMedCrossRef
104.
go back to reference Donnelly AL, Glass M, Minkwitz MC, et al. The leukotriene D4—receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995; 151: 1734–9PubMed Donnelly AL, Glass M, Minkwitz MC, et al. The leukotriene D4—receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995; 151: 1734–9PubMed
105.
go back to reference Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene—receptor antagonist, for the treatment of mild asthma and exercise—induced bronchoconstriction. N Engl J Med 1998; 39: 47–52 Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene—receptor antagonist, for the treatment of mild asthma and exercise—induced bronchoconstriction. N Engl J Med 1998; 39: 47–52
106.
go back to reference Villaran C, O’Neill SJ, Helbling A, et al. Montelukast versus salmeterol in patients with asthma and exercise—induced bronchoconstriction. J Allergy Clin Immunol 1999; 104: 547–53PubMedCrossRef Villaran C, O’Neill SJ, Helbling A, et al. Montelukast versus salmeterol in patients with asthma and exercise—induced bronchoconstriction. J Allergy Clin Immunol 1999; 104: 547–53PubMedCrossRef
107.
go back to reference Melo RE, Sole D, Naspitz CK. Exercise—induced bronchoconstriction in children: montelukast attenuates the immediate phase and late—phase responses. J Allergy Clin Immunol 2003; 111: 301–7PubMedCrossRef Melo RE, Sole D, Naspitz CK. Exercise—induced bronchoconstriction in children: montelukast attenuates the immediate phase and late—phase responses. J Allergy Clin Immunol 2003; 111: 301–7PubMedCrossRef
108.
go back to reference Peroni DG, Piacentini GL, Ress M, et al. Time efficacy of a single dose of montelukast on exercise—induced asthma in children. Pediatr Allergy Immunol 2002; 13: 434–7PubMedCrossRef Peroni DG, Piacentini GL, Ress M, et al. Time efficacy of a single dose of montelukast on exercise—induced asthma in children. Pediatr Allergy Immunol 2002; 13: 434–7PubMedCrossRef
109.
go back to reference Rundell KW, Spiering BA, Baumann JM, et al. Effects of montelukast on airway narrowing from eucapnic voluntary hyperventilation and cold air exercise. Br J Sports Med 2005; 39: 232–6PubMedCrossRef Rundell KW, Spiering BA, Baumann JM, et al. Effects of montelukast on airway narrowing from eucapnic voluntary hyperventilation and cold air exercise. Br J Sports Med 2005; 39: 232–6PubMedCrossRef
110.
go back to reference Helenius I, Lumme A, Öunap J, et al. No effect of montelukast on asthma—like symptoms in ice—hockey players. Allergy 2004; 59: 39–44PubMedCrossRef Helenius I, Lumme A, Öunap J, et al. No effect of montelukast on asthma—like symptoms in ice—hockey players. Allergy 2004; 59: 39–44PubMedCrossRef
111.
go back to reference Sandsund M, Sue-Chu M, Reinertsen RE, et al. Treatment with inhaled beta2−agonists or oral leukotriene antagonists do not enhance physical performance in nonasthmatic highly—trained athletes exposed to −15°C. J Thermal Biol 2000; 25: 181–5CrossRef Sandsund M, Sue-Chu M, Reinertsen RE, et al. Treatment with inhaled beta2−agonists or oral leukotriene antagonists do not enhance physical performance in nonasthmatic highly—trained athletes exposed to −15°C. J Thermal Biol 2000; 25: 181–5CrossRef
112.
go back to reference Sue-Chu M, Sandsund M, Holand B, et al. Montelukast does not affect exercise performance at subfreezing temperature in highly trained non asthmatic endurance athletes. Int J Sports Med 2000; 21: 424–8PubMedCrossRef Sue-Chu M, Sandsund M, Holand B, et al. Montelukast does not affect exercise performance at subfreezing temperature in highly trained non asthmatic endurance athletes. Int J Sports Med 2000; 21: 424–8PubMedCrossRef
113.
go back to reference Mc Kenzie DC, Stewart IB. Asthma medications as ergogenic aids. In: Wilbur R, Lemanske R, Rundell K, editors. Asthma and exercise. Champaign (IL): Human Kinetics, 2002: 237–56 Mc Kenzie DC, Stewart IB. Asthma medications as ergogenic aids. In: Wilbur R, Lemanske R, Rundell K, editors. Asthma and exercise. Champaign (IL): Human Kinetics, 2002: 237–56
114.
go back to reference Spooner C, Rowe BH, Saunders LD. Nedocromil sodium in the treatment of exercise—induced asthma: a meta—analysis. Eur Respir J 2000; 16: 30–7PubMedCrossRef Spooner C, Rowe BH, Saunders LD. Nedocromil sodium in the treatment of exercise—induced asthma: a meta—analysis. Eur Respir J 2000; 16: 30–7PubMedCrossRef
115.
116.
go back to reference Spooner CH, Spooner GR, Rowe BH. Mast—cell stabilizing agents to prevent exercise—induced bronchoconstriction. Cochrane Database Syst Rev 2003; (4): CD002307 Spooner CH, Spooner GR, Rowe BH. Mast—cell stabilizing agents to prevent exercise—induced bronchoconstriction. Cochrane Database Syst Rev 2003; (4): CD002307
117.
go back to reference Briner Jr WW. Introduction: exercise and allergy. Med Sci Sports Exerc 1992; 24: 843–4PubMed Briner Jr WW. Introduction: exercise and allergy. Med Sci Sports Exerc 1992; 24: 843–4PubMed
118.
go back to reference Kobayashi RH, Mellion MB. Exercise—induced asthma, anaphylaxis, and urticaria. Prim Care 1991; 18: 809–13PubMed Kobayashi RH, Mellion MB. Exercise—induced asthma, anaphylaxis, and urticaria. Prim Care 1991; 18: 809–13PubMed
119.
go back to reference Montgomery LC, Deuster PA. Effects of antihistamine medications on exercise performance: implications for sportspeople. Sports Med 1993; 15: 179–95PubMedCrossRef Montgomery LC, Deuster PA. Effects of antihistamine medications on exercise performance: implications for sportspeople. Sports Med 1993; 15: 179–95PubMedCrossRef
120.
go back to reference Mac Knight JM, Mistry DJ. Allergic disorders in the athlete. Clin Sports Med 2005; 24: 507–23CrossRef Mac Knight JM, Mistry DJ. Allergic disorders in the athlete. Clin Sports Med 2005; 24: 507–23CrossRef
121.
go back to reference Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systemic review of randomised controlled trials. BMJ 1998; 317: 1624–9PubMedCrossRef Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systemic review of randomised controlled trials. BMJ 1998; 317: 1624–9PubMedCrossRef
122.
go back to reference Carrozzi FM, Katelaris CH, Burke TV, et al. An open study examining the effects of intranasal budesonide on quality of life and performance in elite athletes with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2001; 107: S154–5 Carrozzi FM, Katelaris CH, Burke TV, et al. An open study examining the effects of intranasal budesonide on quality of life and performance in elite athletes with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2001; 107: S154–5
123.
go back to reference Walker SM, Pajno GB, Lima MT, et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized clinical trial. J Allergy Clin Immunol 2001; 107: 87–93PubMedCrossRef Walker SM, Pajno GB, Lima MT, et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized clinical trial. J Allergy Clin Immunol 2001; 107: 87–93PubMedCrossRef
124.
go back to reference Katelaris CH, Carrozzi FM, Burke TV, et al. Patterns of allergic reactivity and disease in Olympic athletes. Clin J Sports Med 2006; 16: 401–5CrossRef Katelaris CH, Carrozzi FM, Burke TV, et al. Patterns of allergic reactivity and disease in Olympic athletes. Clin J Sports Med 2006; 16: 401–5CrossRef
125.
go back to reference Hodges K, Hancock S, Currell K, et al. Pseudoephedrine enhances performance in 1500−m run. Med Sci Sports Exerc 2006; 38: 329–33PubMedCrossRef Hodges K, Hancock S, Currell K, et al. Pseudoephedrine enhances performance in 1500−m run. Med Sci Sports Exerc 2006; 38: 329–33PubMedCrossRef
126.
go back to reference Gill ND, Shield A, Blazevich AJ, et al. et al. Muscular and cardiorespiratory effects of pseudoephedrine in human athletes. Br J Clin Pharmacol 2000; 50: 205–13PubMedCrossRef Gill ND, Shield A, Blazevich AJ, et al. et al. Muscular and cardiorespiratory effects of pseudoephedrine in human athletes. Br J Clin Pharmacol 2000; 50: 205–13PubMedCrossRef
127.
128.
129.
go back to reference Khaliq Y, Zhanel GG. Fluoroquinolone—associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003; 36: 1404–10PubMedCrossRef Khaliq Y, Zhanel GG. Fluoroquinolone—associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003; 36: 1404–10PubMedCrossRef
130.
go back to reference Van der Linden P, Van Puijenbroek EP, Feenstra J, et al. Tendon disorders attributed to fuoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998. Arthritis Care Res 2001; 45: 235–9CrossRef Van der Linden P, Van Puijenbroek EP, Feenstra J, et al. Tendon disorders attributed to fuoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998. Arthritis Care Res 2001; 45: 235–9CrossRef
131.
go back to reference Williams RJ, Attia E, Wickiewicz TL, et al. The effect of ciprofloxacin on tendon, paratenon, and capsular fibroblast metabolism. Am J Sports Med 2000; 28: 364–9PubMed Williams RJ, Attia E, Wickiewicz TL, et al. The effect of ciprofloxacin on tendon, paratenon, and capsular fibroblast metabolism. Am J Sports Med 2000; 28: 364–9PubMed
132.
go back to reference Vanek D, Saxena A, Boggs JM, et al. Fluoroquinolone therapy and Achilles tendon rupture. J Am Podiatr Med Assoc 2003; 93: 333–5PubMed Vanek D, Saxena A, Boggs JM, et al. Fluoroquinolone therapy and Achilles tendon rupture. J Am Podiatr Med Assoc 2003; 93: 333–5PubMed
133.
go back to reference Lapointe BM, Fremont P, Cote CH. Influence of nonsteroidal anti—inflammatory drug treatment duration and time of onset on recovery from exercise induced muscle damage in rats. Arch Phys Med Rehabil 2003; 84: 651–5PubMed Lapointe BM, Fremont P, Cote CH. Influence of nonsteroidal anti—inflammatory drug treatment duration and time of onset on recovery from exercise induced muscle damage in rats. Arch Phys Med Rehabil 2003; 84: 651–5PubMed
134.
go back to reference Järvinen TAH, Järvinen TLN, Kääriäinen M, et al. Muscle injuries: biology and treatment. Am J Sports Med 2005; 33: 745–64PubMedCrossRef Järvinen TAH, Järvinen TLN, Kääriäinen M, et al. Muscle injuries: biology and treatment. Am J Sports Med 2005; 33: 745–64PubMedCrossRef
Metadata
Title
Use of Prescription Drugs in Athletes
Authors
Dr Antti Alaranta
Hannu Alaranta
Ilkka Helenius
Publication date
01-06-2008
Publisher
Springer International Publishing
Published in
Sports Medicine / Issue 6/2008
Print ISSN: 0112-1642
Electronic ISSN: 1179-2035
DOI
https://doi.org/10.2165/00007256-200838060-00002

Other articles of this Issue 6/2008

Sports Medicine 6/2008 Go to the issue

Review Article

Anabolic Steroid Use